Pfizer will internally separate its commercial operations into three business segments. Two of the three units will include innovative businesses while the other will include Pfizer’s “Value business line.” All three segments will operate in both established and emerging markets. Ian Read, Pfizer’s chairman and chief executive officer, commented, “This represents the next steps in Pfizer’s journey to further revitalize our innovative core, enhance the value of our consum...